Related Experiment Video
Updated: Jan 2, 2026
Merkel Cell Polyomavirus Infection and Detection
Published on: February 7, 2019
Recent advances in Merkel cell carcinoma
Caitlin G Robinson1, Daniel Tan2, Siegrid S Yu2
1Colorado Springs Dermatology Clinic, 170 South Parkside Drive, Colorado Springs, CO, 80910, USA.
Abstract:
Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin cancer that has been historically associated with limited treatment options and poor prognosis. In the past 10 years, research in MCC has progressed significantly, demonstrating improved outcomes when treating with immunotherapy, particularly PD-1/PD-L1 inhibitors, when compared with conventional chemotherapy. There is also increasing evidence of the abscopal effect, a phenomenon describing the regression of untreated, distant MCC tumors following local radiation therapy. Additionally, antibodies to Merkel cell polyomavirus oncoproteins have been found to correlate with disease burden in a subset of patients, providing a useful tool for surveillance after treatment. Guidelines for the management of MCC will likely continue to change as research on surveillance and treatment of MCC continues.
Insights
Merkel cell carcinoma (MCC) treatment has advanced with immunotherapy, especially PD-1/PD-L1 inhibitors, showing better outcomes than chemotherapy. Research also explores the abscopal effect and viral markers for improved MCC surveillance and management.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine skin cancer.
- Historically, MCC has faced limited treatment options and poor prognosis.
- Recent advancements have significantly improved understanding and management of MCC.
Purpose of the Study:
- To summarize recent progress in Merkel cell carcinoma research.
- To highlight advancements in MCC treatment modalities and surveillance.
- To discuss the evolving landscape of MCC management.
Main Methods:
- Review of recent scientific literature on Merkel cell carcinoma.
- Analysis of treatment outcomes comparing immunotherapy with chemotherapy.
- Investigation of the abscopal effect in MCC.
- Evaluation of Merkel cell polyomavirus oncoprotein antibodies for surveillance.
Main Results:
- Immunotherapy, particularly PD-1/PD-L1 inhibitors, demonstrates improved outcomes compared to conventional chemotherapy for MCC.
- Evidence supports the abscopal effect, where local radiation therapy can induce regression of distant MCC tumors.
- Antibodies to Merkel cell polyomavirus oncoproteins serve as a potential tool for monitoring disease burden and surveillance in a subset of patients.
Conclusions:
- Current research indicates a paradigm shift in MCC treatment towards immunotherapy.
- The abscopal effect and viral markers offer new avenues for therapeutic and surveillance strategies.
- Ongoing research is expected to further refine management guidelines for Merkel cell carcinoma.
Related Concept Videos
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...